eIF2B Modulators for Neurodegenerative Disease Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for neurodegenerative diseases such as Alzheimer's, Parkinson's, ALS, and frontotemporal dementia are inadequate, and there is a need for therapeutic agents that can effectively modulate the activity of eukaryotic initiation factor 2B (eIF2B) to address the underlying pathologies.

Innovation Solution

Development of small molecule modulators that target eIF2B, specifically compounds that can modulate the activity of eIF2B, inhibit its phosphorylation, or interfere with the interaction between eIF2B and phosphorylated eIF2, thereby regulating protein synthesis and the integrated stress response pathway.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments for neurodegenerative diseases are used, then existing therapeutic options are available, but they are inadequate and cannot effectively modulate eIF2B activity to address underlying pathologies

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidability to modulate eIF2B activity

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The invention segments the therapeutic approach by targeting specific molecular components (eIF2B complex with its five subunits) rather than using broad-spectrum treatments. The compounds are designed to specifically modulate eIF2B activity, providing a targeted intervention that addresses the root cause of neurodegenerative diseases through selective inhibition of the eIF2B-eIF2 interaction.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The invention introduces small molecule compounds as intermediaries that mediate the modulation of eIF2B activity. These compounds act as molecular mediators between the therapeutic agent and the eIF2B complex, enabling controlled inhibition of the guanine nucleotide exchange factor activity and thereby regulating the integrated stress response pathway.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Productivity

If eIF2B activity is left unmodulated, then protein synthesis continues normally, but stress granule formation and ATF4 expression increase leading to neurodegeneration

Engineering Contradiction:

Improveprotein synthesisVSAvoidstress granule formation and neurodegeneration

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The invention applies preliminary anti-action by pre-inhibiting eIF2B activity before stress granule formation and ATF4 expression can occur. The compounds prevent the pathological cascade by blocking the eIF2B-eIF2 interaction in advance, thereby preventing the formation of stress granules and the subsequent expression of ATF4 that would otherwise lead to neurodegeneration.

Inventive Principle:

Principle #9Preliminary anti-action

Solution Approach 2:

The invention converts the harmful overactivation of the integrated stress response into a beneficial effect by using compounds that selectively inhibit eIF2B. This controlled inhibition prevents the formation of toxic stress granules while maintaining essential protein synthesis, thereby transforming a potentially harmful pathway into a protective mechanism against neurodegeneration.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS20250122159A1Compounds, compositions and methods

Publication Date: 2025.04.17 DENALI THERAPEUTICS INC

AI summary

The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.